Acta Scientific Ophthalmology (ASOP)
Case Study Volume 3 Issue 3
Maaly Abdel Halim Abdel Fattah1,2,3*, Fatima Babiker Ali Babiker3 and Selwa Abdulla Alhazzaa2,3
1Ophthalmology Department, Cairo University, College of medicine, Cairo, Egypt
2Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3Al-Faisal University college of Medicine, Riyadh, Saudi Arabia
*Corresponding Author: Maaly Abdel Halim Abdel Fattah, Ophthalmology Department, Cairo University, College of medicine, Cairo, Egypt and Ophthalmology Department, King Faisal Specialist Hospital and Research Center and Al-Faisal University college of Medicine, Riyadh, Saudi Arabia.
Received: February 02, 2020; Published: February 24, 2020
Abstract
Sunitinib and Ponatinib are two biological drugs that have greatly contributed to the treatment advances of different types of cancer. However, the ocular adverse effects of those drugs were not well studied and only a few case reports, within the literature, described patients who developed vision loss and ocular changes. In this study, we reported the clinical presentation of the first two Saudi patients presenting with a sudden loss of vision due to recent lines of treatment. The effect of these drugs has strongly implied the importance of cautious use and the need for further studies on their ocular side effects.
Keywords:Blindness; Ocular; Biological; Sunitinib; Ponatinib and Anticancer
References
- Centre for Drug Evaluation and Research. “FDA Requires Multiple New Safety Measures for Leukaemia Drug (www.Iclusig.com)” U.S. Food and Drug Administration (2018)
- Wegner A and R Khoramnia. “Neurosensory Retinal Detachment Due to Sunitinib Treatment”. Eye 25.11 (2011): 1517-1518.
- Fraunfelder Frederick T., et al. “Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events.” Mary Ann Liebert, Inc., Publishers 34.6 (2018): 632-635.
- Elizondo Leal José A., et al. “Optic Neuropathy in Extramedullary, Blast Crisis of Chronic Myeloid Leukemia”. Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie, U.S. National Library of Medicine (2019).
Citation
Citation: Maaly Abdel Halim Abdel Fattah., et al. “Sudden Iatrogenic Blindness in Patients Treated with Biological Cancer Therapy”. Acta Scientific Ophthalmology 3.3 (2020): 13-15.
Copyright
Copyright: © 2020 Maaly Abdel Halim Abdel Fattah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Journal Menu
Metrics
Indexed In
News and Events
- Certification for Review
Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals. - Submission Timeline for Upcoming Issue
The last date for submission of articles for regular Issues is December 25, 2024. - Publication Certificate
Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work. - Best Article of the Issue
The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
